What question did this study set out to answer?

This research aims to explore participant experiences in the INTERCEPT-AD trial for early Alzheimer's disease.

March 26, 2026Trials0 citationsOpen Access

Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer’s disease: a qualitative interview study

EMElizabeth MerikleOutcomes Research Consortium CPCarrie PresnallFilm Independent TFTodd FeasterAcumen Pharmaceuticals (United States)

Key Points

This research aims to explore participant experiences in the INTERCEPT-AD trial for early Alzheimer's disease.
Conducted qualitative interviews with trial participants
Analyzed feedback to identify common burdens and logistical issues
Performed exploratory gender analyses on experiences
Identified key trial-related burdens affecting participant experiences
Gained insights from gender analyses, highlighting unique experiences
Suggested the need for broader analyses including race/ethnicity

Abstract

Study findings suggest opportunities to enhance the AD trial experience by addressing trial-related burdens and logistical aspects of participation. Exploratory gender analyses yielded additional insight into the patient trial experience but should be further examined along with race/ethnicity and study partner characteristics to enhance clinical study design and execution.

Demander à l'IA

Bookmark

View Full Paper